

BIOLOGICS
MANUFACTURING DACH 2027

**THE PREMIER
BIOPHARMA
GATHERING DRIVING
BIOPROCESS
INNOVATION &
MARKET GROWTH
ACROSS THE DACH
REGION**

📅 17–18 February 2027

OFFICIAL EVENT BROCHURE

<https://infohub.imapac.com/biologics-manufacturing-dach-2027>

Table of Contents

What is new in 2027?	3
Agenda at a Glance	4
Agenda	5
Meet the Speakers	11
Sponsors & Media Partner	14
Our Past Partners	15
DACH Series Past Partners	18
Expected Audience Snapshot	19
Targeted Attendees List	20
Sponsorship Packages	22
Sponsorship Opportunities	23
Testimonials	24
Add to Calendar	27
About IMAPAC	28

EVENT HIGHLIGHTS

500+
ATTENDEES

200+
COMPANIES

60+
EXPERT
SPEAKERS

DATE & VENUE

17-18 February 2027

Munich
Germany

CO-LOCATED EVENTS



About the Event

WHAT IS NEW IN 2027?

BIOLOGICS MANUFACTURING DACH 2027

This year introduces the DACH Bioprocessing Excellence Awards, recognising manufacturing innovation, operational excellence, and leadership across cell & gene therapy, biologics, and oligos & peptides.

The programme brings cell & gene therapy, biologics, and oligos & peptides together in one agenda, reflecting the shift toward multi-platform and hybrid manufacturing models.

There is a stronger emphasis on late-stage CMC, tech transfer, GMP readiness, and cost-of-goods, aligning discussions with real-world commercialisation challenges.

New sessions highlight digital and automated manufacturing, including digital twins, PAT, real-time release testing, and closed-system operations.

The agenda places greater focus on patient-centric and decentralized CGT models, covering autologous manufacturing, point-of-care production, and chain of identity.

Discussions are tailored to DACH-specific operational and sustainability priorities, including facility design, supplier risk, energy efficiency, and regional regulatory expectations.

WHAT TO EXPECT



500+

Senior Attendees



60+

Expert Speakers



200+

Companies Represented

Agenda at a Glance

DAY 1 17 FEBRUARY 2027	DAY 2 18 FEBRUARY 2027
BIOLOGICS MANUFACTURING DACH 2027	BIOLOGICS MANUFACTURING DACH 2027
The Future of Biologics Manufacturing: Building Scalable, Resilient and Intelligent Operations	Advancing CMC for Next-Generation Biologics
NETWORKING BREAK	
Next-Generation Upstream Manufacturing	Novel Approaches to Biosafety Testing
LUNCH	
Optimising Downstream Throughput	AI, Digitalisation & Smart Biomufacturing
NETWORKING BREAK	
Industry Roundtables: Solving Tomorrow's Manufacturing Challenges Today	Building Flexible Facilities for a Multi- Modality Future
END OF CONFERENCE DAY 1	END OF CONFERENCE

Day 1

17 February 2027

08:00

Registration & Coffee

08:50

Chairman's Welcome Address

Nicoletta Loggia

Chief Technology Officer, Orchard Therapeutics, Switzerland

The Future of Biologics Manufacturing

09:00

Commercial Manufacturability by Design: Why Scale-Up Success Starts During Development

- Integrating manufacturability into early development
- Bridging process development and commercial manufacturing
- Embedding QbD and process understanding from day one
- Avoiding costly scale-up and tech transfer failures

09:30

Reserved for Solution Provider

10:00

PANEL DISCUSSION

The Biologics Factory of 2030: AI, Digital Twins and the Future of Manufacturing Excellence

- Where AI is delivering value today
- Digital twins versus reality
- PAT and real-time process understanding
- Building GMP-compliant digital manufacturing environments

PANELISTS

Dr. Ulrich Rümenapp

Senior Biotech Program Lead, Bayer, Germany

Bettina Knapp

Head of Digital Operations Drug Substance, Boehringer Ingelheim Pharma, Germany

10:30

Networking Break

Next-Generation Upstream Manufacturing

11:10

The Intensification Paradox: When More Upstream Productivity Creates Downstream Problems

- Are upstream teams optimising the wrong KPIs?
- When increased titres overwhelm downstream capacity
- Facility implications of intensified processes
- Balancing yield, quality and throughput

11:40

Reserved for Solution Provider

12:10

AI-Driven Upstream Development: Can Digital Twins Predict Scale-Up Success?

- Current state of digital twin deployment
- Predictive cell culture modelling
- AI-assisted process development
- Separating hype from practical value

13:00

Lunch

Optimising Downstream Throughput

14:00

Maximising Yield Without Compromising Quality in Commercial Biologics Manufacturing

- Reducing product loss across the manufacturing process
- Balancing yield and product quality
- Process robustness at commercial scale
- Cost-of-goods optimisation

14:30

Reserved for Solution Provider

15:00

From Process Understanding to Product Quality: Linking CPPs, CQAs and Downstream Performance

- Process understanding strategies
- Managing critical quality attributes
- Data-driven validation
- Regulatory expectations for commercial manufacturing

15:30

Networking Break

16:00

ROUNDTABLE DISCUSSION

1. Integrating AI into GMP Environments Without Compromising Compliance (TBC)
Alessio Epifanio — Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine, Italy
2. Bridging the Gap Between Process Development and Commercial Manufacturing (TBC)
3. Biomanufacturing Without Silos: Connecting Development, Manufacturing, Quality and Supply Chain
4. Building Supply Chain Resilience in an Era of Geopolitical Uncertainty
5. Beyond the Contract: What Does a True Manufacturing Partnership Look Like?

17:00

Cocktail Reception

17:15

END OF CONFERENCE DAY 1

Day 2

18 February 2027

08:00

Registration & Coffee

08:50

Chairman's Welcome Address

Advancing CMC for Next-Generation Biologics

09:00

Platform Processes Are Not Plug-and-Play: Adapting CMC Strategies for Complex Biologics

- When platform processes accelerate development
- When customisation becomes essential
- CMC considerations for ADCs and emerging modalities
- Balancing speed and flexibility

Melanie Dannemeyer

Associate Director Tech Transfer, AstraZeneca, Sweden

09:30

Reserved for Solution Provider

10:00

Driving Efficiency in Quality Operations through LEAN Thinking

- Flow Efficiency vs. Resource Efficiency
- Examples from QC, Deviation Handling and Documentation Management
- LEAN Leadership Behaviors

Frank Seibel

Quality Site Head, Vice President, Roche, Germany

10:30

Networking Break

Novel Approaches to Biosafety Testing

11:10

Building a Risk-Based Biosafety Testing Strategy for Complex Biologics

- Defining biosafety-testing requirements based on product modality, process risk, and development stage
- Integrating rapid and compendial methods without compromising data integrity or regulatory acceptability
- Establishing clear decision pathways for atypical results, investigations, and batch-impact assessment
- Aligning development, quality, manufacturing, and external testing partners around a coherent testing strategy

Baerbel Grossmann

Associate Director Global Regulatory Affairs CMC Biologics, Sanofi, Germany

11:40

Reserved for Solution Provider

12:10

From Cell Bank to Commercial Supply: Strengthening Contamination Control Across the Biologics Lifecycle

- Building viral-safety strategy into cell-bank qualification
- Identifying contamination risks across the manufacturing process
- Using monitoring and trend analysis to strengthen control
- Protecting supply continuity during investigations and scale-up

13:00

Lunch**AI, Digitalisation & Smart Biomanufacturing**

14:00

PANEL DISCUSSION**Smart Manufacturing for a Sustainable Future (TBC)**

- AI and digital tools for greener manufacturing operations
- Improving resource efficiency through connected manufacturing
- Building resilient and sustainable production networks
- Measuring sustainability through real-time operational insights

Alessio Epifanio

Director, Environmental Health, Safety & Sustainability, J&J Innovative Medicine, Italy

Roberto Corazza

Operational Excellence, Digital and Strategy Director, J&J Innovative Medicine, Italy

14:30

Reserved for Solution Provider

15:00

AI-Driven Supply Chain Strategy for Biologics: Preparing for 2030 (TBC)

- AI-driven demand forecasting and capacity planning
- Predicting supply risks before they impact operations
- Building more agile and resilient manufacturing networks
- From reactive planning to autonomous supply chain decision-making

Maximilian Abress

Senior Director Global Supply Chain, BioNTech, Germany

Karin Keppeler

Associate Director E2E Supply Chain, BioNTech, Germany

15:30

Networking Break

Building Flexible Facilities for a Multi-Modality Future

16:00

Single-Use vs Stainless Steel: What Will Define the Next Generation of Biomanufacturing?

- Drivers behind the shift toward single-use technologies
- When stainless steel still makes strategic sense
- Supporting flexible manufacturing models
- Implications for scale, cost, and operational efficiency

16:30

Designing Facilities for Process Intensification and Perfusion Manufacturing

- Facility implications of intensified processing
- Supporting perfusion at commercial scale
- Infrastructure requirements for higher productivity
- Balancing flexibility and capacity

17:00

Closing Remarks

17:15

END OF CONFERENCE DAY 1

MEET THE SPEAKERS

BIOLOGICS
MANUFACTURING DACH 2027



Baerbel Grossmann

Associate Director Global Regulatory
Affairs CMC Biologics

Sanofi
GERMANY



Bettina Knapp

Head of Digital Operations Drug
Substance

Boehringer Ingelheim Pharma
GERMANY



Alessio Epifanio

Director, Environmental Health, Safety &
Sustainability

J&J Innovative Medicine
ITALY



Melanie Dannemeyer

Associate Director Tech Transfer

AstraZeneca
SWEDEN



Frank Seibel

Quality Site Head, Vice President

Roche
GERMANY



Maximilian Abress

Senior Director Global Supply Chain

BioNTech
GERMANY



Karin Keppeler

Associate Director E2E Supply Chain

BioNTech
GERMANY



Roberto Corazza

Operational Excellence, Digital and
Strategy Director

J&J Innovative Medicine
ITALY

CGT MANUFACTURING
DACH 2027



CHAIRMAN

Nicoletta Loggia

Chief Technology Officer
Orchard Therapeutics
SWITZERLAND



Marion Hitchcock

Managing Director Gene & Cell
Therapies Incubator
Bayer
GERMANY



Chris Baldwin

Vice President, Manufacturing
and Supply
Resolution Therapeutics
UK



**Gulbengu Kuzgun
Yuksel**

Network Head of Quality Cell &
Gene Therapy
Roche
SWITZERLAND



**Bart Van
Waeyenberge**

EMEA Head of CAR T
Operations
Johnson & Johnson
BELGIUM



Parag Kumthekar

Lead Gene Therapy
Downstream Team
UCB
BELGIUM



Volker Derdau

Head Center of Excellence
Isotope Chemistry, Senior
Distinguished Scientist

Sanofi
GERMANY



Dr. Ulrich Rümenapp

Senior Biotech Program Lead
Bayer

GERMANY



Hagen Cramer

Chief Technology Officer
QurAlis

USA



Dr. Cecile Brocard

Head of Downstream
Development
Boehringer Ingelheim

AUSTRIA



**Karoline Bechtold-
Peters**

Director Science & Technology -
Scientific Office/Drug Product
Development/Global Biologics &
CGT

Novartis
SWITZERLAND



Carl Reens

Principal Scientist, Global
Chemical Development

AstraZeneca
UK



Gnana Oli Rajaraman

Associate Director Bioanalytics

AiCuris
GERMANY

Sponsors & Media Partner

GOLD

clean cells
SOLUTION FOR BIOLOGICS

BioReliance®
Contract Testing Services


Our Past Partners





Our Past Partners (cont.)

Our Past Partners (cont.)



DACH Series Past Partners

 Minaris Advanced Therapies	 CellforCURE in SEQUENCING	 cytiva	 BioProduction by SEKISUI	 INPROCESS ILSF Industrial Research & Development	 clean cells SOLUTION FOR BIOLOGICS
 team	 SGS	 EMERSON	 ZETA	 c-LEcta	 BIONAUT
 SYMCEL [®]	 OXGENE [®] A Multi-Advanced Therapies Company	 CAPRICORN SCIENTIFIC	 THINKCYTE	 AdipoGen [®] LIFE SCIENCES	 BIO-RAD
 EurekaBio	 GENESPIRE	 Deloitte.	 time:matters	 ips	 Microsynth THE SWISS DNA COMPANY
 INVITRIA	 Mytos	 QIAGEN	 Starlab	 AP-PROCESS	 HSE-AG
 cencora	 ALEXION	 LITBioSciences	 ellab	 ARDMAC Building Better	 OPES DIAGNOSTICS
 BIOCAIR	 eppendorf	 GMP Healthcare Ltd Pharmaceutical Quality & Compliance	 bit.bio	 DATWYLEI	 ASYMCHAM
 INTELSIUS [®] A LUNAR CORPORATION	 Roche	 WuXi Biologics Global Solution Provider	 PathoQuest	 CG PHARMA & BIOTECH	 ProBio
 Just EVOTEC BIOLOGICS	 Boehringer Ingelheim	 MENARINI BIOTECH	 Coriolis Pharma	 olon	 octapharma [®]
 SARTORIUS					

Expected Audience Snapshot

98%

BIOPHARMA & BIG PHARMA

2%

SERVICE & SOLUTION PROVIDERS

BY PROFILE

Emerging / Mid-size Biotech	53%
Large Pharma & Biopharma Manufacturers	41%
CDMOs (Lonza, Evotec, Rentschler)	4%
Academia & Research Institutes	1%
Regulatory / Service & Consulting	1%


BY JOB TITLE

CMC / Pharmaceutical Development	36%
Process Development, MSAT & Tech Transfer	23%
Manufacturing & Operations	11%
Other / General Management (unmatched titles)	8%
Executive Leadership (C-Suite/Founders)	6%
Quality & Compliance	5%
Supply Chain & External Manufacturing	5%
R&D / Scientific	3%
Regulatory Affairs	3%

DECISION MAKERS

Decision Makers	99%
Others	1%

BY GEOGRAPHY



Targeted Attendees List

Companies and senior roles represented across the selected event(s)

BIOLOGICS MANUFACTURING DACH 2027

JOB TITLE	COMPANY	COUNTRY
Job Title	Company	Country
Director, Analytical Development	Valneva	Austria
Associate Director, Manufacturing	MorphoSys	Germany
Head of External Manufacturing	Formycon	Germany
Proposal Manager	Rentschler Biopharma	Germany
Chief Technology Officer	QurAlis	United States
Head of CMC	Boehringer Ingelheim	Germany
Director, Biopharmaceutical Development	Lonza	Switzerland
Senior Director, MSAT	Novartis	Switzerland
Director, Manufacturing Science & Technology	Ribbon Biolabs	Austria
Chief Technical Operations Officer	T-Knife	Switzerland
Director CMC Proteins	BioNTech	Germany
Head of External Manufacturing	Ferring Pharmaceuticals	Switzerland
Head of CMC	invIOs	Austria
Senior Director, MSAT	Valneva	Austria
Head of External Manufacturing	Boehringer Ingelheim	Germany
Head of CMC	MorphoSys	Germany
Head of RNA Therapeutics	invIOs	Austria
Head of Biology	Ikarovec Ltd	United Kingdom
Director, Analytical Development	Valneva	Austria
Associate Director, Manufacturing	MorphoSys	Germany

Targeted Attendees List (cont.)

BIOLOGICS MANUFACTURING DACH 2027

JOB TITLE	COMPANY	COUNTRY
Head of External Manufacturing	Formycon	Germany
Proposal Manager	Rentschler Biopharma	Germany
Chief Technology Officer	QurAlis	United States
Head of CMC	Boehringer Ingelheim	Germany
Director, Biopharmaceutical Development	Lonza	Switzerland
Senior Director, MSAT	Novartis	Switzerland
Director, Manufacturing Science & Technology	Ribbon Biolabs	Austria
Chief Technical Operations Officer	T-Knife	Switzerland
Director CMC Proteins	BioNTech	Germany
Head of External Manufacturing	Ferring Pharmaceuticals	Switzerland
Head of CMC	invIOs	Austria
Senior Director, MSAT	Valneva	Austria
Head of External Manufacturing	Boehringer Ingelheim	Germany
Head of CMC	MorphoSys	Germany
Head of RNA Therapeutics	invIOs	Austria
Head of Biology	Ikarovec Ltd	United Kingdom

[VIEW THE FULL ATTENDEE LIST →](#)

Sponsorship Opportunities

Sponsorship Packages

DIAMOND

PACKAGE INCLUDES

- ✓ Full-day workshop for 30 pax: room, lunch, 2 refreshment breaks, coffee / tea
- ✓ Keynote solo presentation: 20 min + 5 min Q&A
- ✓ 25-minute end-user client case study
- ✓ 12 sqm exhibition space (4x3m booth + banner)
- ✓ 1 speaker pass; 7 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

PLATINUM

PACKAGE INCLUDES

- ✓ Half-day workshop for 30 pax: room, 1 refreshment break, coffee / tea
- ✓ Prime-billing solo presentation: 20 min + 5 min Q&A
- ✓ 25-minute end-user client case study
- ✓ 12 sqm exhibition space (4x3m booth + banner)
- ✓ 1 speaker pass; 7 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

GOLD

PACKAGE INCLUDES

- ✓ Prime-billing solo presentation: 20 min + 5 min Q&A
- ✓ 9 sqm exhibition space (3x3m booth + banner)
- ✓ 1 speaker pass; 5 guest passes; 2 exhibitor passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

SILVER (ENHANCED)

PACKAGE INCLUDES

- ✓ Solo presentation: 20 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 speaker pass; 3 guest passes; 2 exhibitor passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

SILVER

PACKAGE INCLUDES

- ✓ Solo presentation: 10 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth + tabletop display)
- ✓ 1 speaker pass; 2 guest passes; 2 exhibitor passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

BRONZE

PACKAGE INCLUDES

- ✓ Solo presentation: 10 min + 5 min Q&A
- ✓ 6 sqm exhibition space (3x2m booth)
- ✓ 1 speaker pass; 2 guest passes
- ✓ Lead retrieval

EXHIBITION + 10 MEETINGS

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ 10 onsite 1:1 meetings
- ✓ Lead retrieval

EXHIBITION + 5 MEETINGS

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ 5 onsite 1:1 meetings
- ✓ Lead retrieval

EXHIBITION

PACKAGE INCLUDES

- ✓ 6 sqm exhibition space (3x2m booth + banner)
- ✓ 1 guest pass; 2 exhibition passes
- ✓ Lead retrieval

Sponsorship Opportunities

BIOLOGICS
MANUFACTURING DACH 2027

Who Should Sponsor?

Bioprocess Equipment Providers

Engineering And Facility Design Firms

Cell Culture Media Providers

Filters And Chromatography Columns

Cell Line Providers

Automation And Process Analytical
Technology Firms

Contract Development and
Manufacturing Organisations

Fill & Finish And Drug Delivery Solutions

Why Sponsor

SPONSORSHIP BENEFITS



Thought Leadership Speaking



Panel Participation



Solution Showcases



Engagement and Visibility
Opportunities



Branding and Digital Visibility



Exclusive Networking

TESTIMONIALS



The Biologics and CGT Manufacturing DACH conference 2026 was very well planned and coordinated. It provided high-quality talks for staying up-to-date in our industry and I specifically enjoyed the time for networking.



Dr Heiner Apeler

VP Head of Biologics Development

Bayer
GERMANY



Thanks for the invite to speak at the event. It was a really enjoyable meeting and a great opportunity to present our work to the community. Identifying key partners for ImmunoKey's development plan is a critical aspect of getting our therapies to patients; the CGT and Biologics Manufacturing DACH meeting offered us the opportunity to engage with key CDMOs who can help us achieve this goal.



John Bridgeman

CSO

Immunokey
UK



Just back from an incredible time at the Biologics Manufacturing DACH congress! I have to be honest - as someone in Procurement, some of the deep-dives into Cell & Gene and biologics development were definitely above my scientific capabilities! However, the exchange of knowledge was fantastic, and it was a privilege to learn from such brilliant minds. A true highlight was the fantastic collaboration with Christopher Pawlak (PhD). I had the privilege of co-hosting a round table with him focused on the impact of tariffs in the biopharma world. Christoph, thank you for the partnership - it was a truly dynamic discussion! 🍌 One of my biggest takeaways is that we have officially entered the era of "The Great Reshoring". We are moving past the days when drug manufacturing decisions were purely scientific; they are now deeply geopolitical. As we discussed in our round table, we can no longer just react to change. We have to treat scenario planning like a muscle that we train constantly to design for volatility. The event really hit home how much our world is changing - from the incredible progress in biologics manufacturing to the AI evolution. I'm excited to see how we can implement these insights to build resilience and benefit BMS biologics manufacturing. Back to my desk, I will start with socializing the learnings with my colleagues. A huge thank you to Drishti G. for the flawless organization and to Noel Murphy for approving the trip and supporting this critical learning opportunity!



Dennis Stelljes

Associate Director, Strategic Sourcing & Procurement, Biologics External Manufacturing

BMS
SWITZERLAND

TESTIMONIALS (cont.)



Really well organised conference with great attendees and high engagement - I was delighted to have taken the time to attend and really enjoyed sharing my thoughts on Accelerating Biologics Pipeline and ensuing discussion. Thank you to all organisers and facilitators



Dr Andrew Kelly

Director, Manufacturing Technology
BMS
IRELAND



A fantastic deep dive into the DACH region's CGT landscape. This conference made one thing clear: efficacy is proven, but industrialization is the new frontier. To truly move the needle, we must look beyond the lab and focus on scaling automation, streamlining supply chains, and tackling COGS. The diversity of voices - from large corporations, to tech suppliers and academic pioneers - provided a 360-degree view of the manufacturing challenges we must solve together.



Dr Thomas Villiger

Professor of Bioprocess Technology
University of Applied Sciences and Arts
Northwestern Switzerland FHNW
SWITZERLAND



Thanks for the invite. The conference was really excellent, due to the caliber and engagement of the attendees.



Brian O'Connor

VP Global Quality
Orchard Therapeutics
UK



Thanks for putting this together! I enjoyed the discussions, atmosphere and engagement of participants. Great to be there!



Alvaro Avivar-Valderas

Associate Director - Cell Therapy Technology & Product Engine
Takeda
SPAIN

TESTIMONIALS (cont.)



I thoroughly enjoyed attending the CGT Manufacturing DACH 2026 by IMAPAC. The program featured exceptionally industry-relevant talks that provided deep insights into the current landscape. Beyond the sessions, the networking opportunities were top-tier, thanks to the high caliber of participants.



Steffen Schulze

Strategic Analytics & Business Analytics Lead
Roche
SWITZERLAND



I had the pleasure of collaborating with the IMAPAC team during the Irish leg of the Biologics World event in February 2026. The organisers were exceptionally receptive and helpful, ensuring a seamless experience throughout the planning, exhibition logistics, partnering sessions, and sponsor visibility. Their proactive approach in connecting us with potential partners significantly enhanced our ROI. We are already exploring future opportunities to work with the IMAPAC team.



Terry Gray

Field Marketing Manager
Merck



Thank you for your email and organising this wonderful event. It was a pleasure to participate. Congratulations on organising this event. It was a wonderful opportunity to present our work and to collaborate with others in the area. Looking forward to your next event



Warren Roche

Senior Statistical Expert
Sanofi
IRELAND



Thank you, it was a pleasure meeting you, and your enthusiasm made it an engaging and positive event. I hope we have opportunity to connect again in the future.



Michael Inglis

Head of Manufacturing Sciences, Analytical Technologies
Chiesi Farmaceutici Global Rare Disease
IRELAND



Well done on a very informative and successful event.



Shada Warreth

Global Partnerships Implementation Senior Manager
NIBRT
IRELAND

MARK YOUR CALENDAR

Save the Date

17–18 FEB
2027 Munich

Biologics Manufacturing DACH 2027



ALL IMAPAC EVENTS

Explore Our Full Event Calendar

Discover upcoming IMAPAC biopharmaceutical conferences, summits, and exhibitions across Europe and worldwide.



OR ADD THIS EVENT TO YOUR CALENDAR

**Google Calendar**

One-click add to Gmail

**Outlook Calendar**

Add to Microsoft Outlook

**Scan to Register**

Open camera, point at code, instant registration access.

Or click the QR to open registration directly.

A VARIETY OF PRODUCTS TO CATER TO GLOBAL BIOPHARMACEUTICAL INDUSTRY'S MARKET INTELLIGENCE AND BUSINESS CONNECTIONS NEEDS.

01 B2B EVENTS

Thought-leadership, industry knowledge-sharing and quality networking are at the core of IMAPAC's B2B events.

Create an engaging experience for your audiences, explore our B2B Events Solutions.

02 360 MARKETING SOLUTIONS

Expand your reach and influence! Be it with customized events, digital marketing solutions, content creation or thought-leadership.

Tap into our global audience spanning the sub-sectors and regions shaping the biopharmaceutical industry.

03 DASHBOARDS

A quick-view analytics tool to power your decisions. Access region or country-specific data to uncover pipeline information, product focus.

Customize the dashboard based on your needs. Drill down to the data you need using custom views.

04 CUSTOM RESEARCH

Based on your objectives and budget, you can customize a package to one that best meets your intelligence needs. This allows you to maximize your ROI without spending on items that are not in line with your strategies.

With access to a database of 60,000+ life science professionals. We conduct research with a highly-qualified audience.

05 REPORTS

Discover in-depth market information of the growing biopharmaceutical sector.

[Learn More →](#)

HELPING THE GLOBAL BIOPHARMACEUTICAL INDUSTRY

Generate Tangible Growth

IMAPAC is the one-stop shop of market intelligence and business connections for the global biopharmaceutical industry. We help companies expand their influence, make data driven decisions through our industry intelligence, and link up with other biopharmaceutical professionals to exchange knowledge and engage in quality networking. At the

core of IMAPAC is our mission to help biopharmaceutical businesses globally generate tangible growth. At the same time, our heart lies in giving back to society. We empower the next generation by equipping underprivileged children with an education.

WEBSITE

imapac.com

EMAIL

info@imapac.com

IMAPAC PTE LTD

36 Robinson Road, #02-01
Singapore 068877
[+65 6983 6140](tel:+6569836140)

IMAPAC UK LTD

77 Farringdon Road, Farringdon
London EC1M 3JU, United Kingdom
[+44 161 552 8507](tel:+441615528507)

CONNECT WITH US

LINKEDIN

[@imapac](#)

X

[@imapac](#)

FACEBOOK

[ImapacPteLtd](#)